Category
Tissue repair & growth
BPC-157, TB-500, GHK-Cu and the IGF-1 variants. The sharpest gap on the site between attention and evidence: these are among the most-read compounds we track and among the least-tested in humans. Not one has an FDA-approved product.
What the record holds for this category
8
Compounds tracked
0
With an FDA-approved product
4
With no registered human study
16
Registered studies, all members
Every compound in this category
Ordered by how many people read the Wikipedia article each month, which measures attention and nothing else. The evidence column is what is actually known.
| Compound | FDA status | Human studies | Evidence | Readership |
|---|---|---|---|---|
| BPC-157 | Research only | 2 | CPhase 1 or 2 only | 31,331 |
| IGF-1 LR3 | Research only | 0 | XNo registered human study | 2,390 |
| TB-500 | Research only | 1 | CPhase 1 or 2 only | 2,321 |
| MGF | Research only | 0 | XNo registered human study | 597 |
| Larazotide | Research only | 10 | BReached phase 3 or 4, not approved | 559 |
| ARA-290 | Research only | 3 | CPhase 1 or 2 only | — |
| Follistatin 344 | Research only | 0 | XNo registered human study | — |
| IGF-1 DES | Research only | 0 | XNo registered human study | — |
Compare within this category
These pairs are the most-read members, picked mechanically. Pairing is not a recommendation and says nothing about which is preferable.
Reading on these compounds
Categories are editorial groupings by mechanism — they are not medical classifications, and membership is not a claim that a compound does what the group name suggests. Study counts include only trials whose registered intervention names the compound. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. How this is put together.